FGD2: A Potential Drug Target for Pain and Cellular Processes

Target Name: FGD2

NCBI ID: G221472

FGD2

FGD2: A Potential Drug Target for Pain and Cellular Processes

FGD2 (FYVE, RhoGEF and PH domain containing 2) is a protein that plays a crucial role in various cellular processes. It is a member of the G-protein-coupled receptor (GPCR) family, which is a large family of transmembrane proteins that play an important role in cellular signaling. FGD2 is expressed in many different tissues and cells in the body, including the brain, eye, and immune system.

The FGD2 gene was first identified in 2002 using transcriptomic analysis of brain-enrichment RNA samples from the mouse. It is located on chromosome 7 and has a calculated gene size of 25.1 kb. FGD2 is a small gene that encodes a protein of 214 amino acids. The protein has a unique structure that consists of an extracellular region, a transmembrane region, and an intracellular region.

FGD2 is a GPCR that is involved in various signaling pathways. One of the most well-studied functions of FGD2 is its role in pain signaling. FGD2 is known to play a key role in the TRPV1 receptor, which is responsible for mediating pain signaling in the body.

In addition to its role in pain signaling, FGD2 is also involved in other cellular processes. For example, it has been shown to play a role in the regulation of cell adhesion, cell migration, and the production of neurotransmitters.

As a potential drug target, FGD2 is an attractive target for researchers because of its unique structure and its involvement in various cellular processes. Many studies have identified potential drug compounds that can modulate the activity of FGD2, including small molecules, peptides, and proteins.

Despite the potential for FGD2 as a drug target, much research is still needed to fully understand its functions and the underlying mechanisms that regulate its activity. FGD2 is a complex protein that is involved in many different cellular processes, and it is likely that many different mechanisms contribute to its function.

Conclusion

In conclusion, FGD2 (FYVE, RhoGEF and PH domain containing 2) is a protein that is involved in various cellular processes in the body. Its unique structure and its involvement in pain signaling, cell adhesion, and neurotransmitter regulation make it an attractive target for drug research. While much research is still needed to fully understand its functions and the underlying mechanisms that regulate its activity, FGD2 is a promising drug target for the future.

Protein Name: FYVE, RhoGEF And PH Domain Containing 2

Functions: Activates CDC42, a member of the Ras-like family of Rho- and Rac proteins, by exchanging bound GDP for free GTP. Activates JNK1 via CDC42 but not RAC1. Binds to phosphatidylinositol 4,5-bisphosphate, phosphatidylinositol 3,4,5-trisphosphate, phosphatidylinositol 5-monophosphate, phosphatidylinositol 4-monophosphate and phosphatidylinositol 3-monophosphate (By similarity)

The "FGD2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FGD2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets